Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome): Defining and Measuring Functional Impacts in Pediatric Patients
source: Orphanet journal of rare diseases
year: 2021
authors: Leiro B,Phillips D,Duiker M,Harmatz P,Charles S
summary/abstract:Research about pediatric patients’ perspective on mucopolysaccharidosis type VI (MPS VI) and its impact on daily life is limited. We aimed to identify the disease concepts of interest that most impact function and day-to-day life of pediatric patients with MPS VI, and to consider clinical outcome assessments (COAs) that may potentially measure meaningful improvements in these concepts.
organization: Phillips Consulting, Chapel Hill, NC, USA. [email protected].DOI: 10.1186/s13023-021-02113-8
read more
BookmarkRelated Content
-
Maroteaux Lamy SyndromeMaroteaux-Lamy syndrome (mucopolysacchar...
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
A Guide to Understanding MPS VIMPS VI (Maroteaux-Lamy syndrome) is caus...
-
Disease Burden, Management Patterns and Multidisciplinary Clinical Approaches for Patients With MPS IVA and VI in Se...There is a paucity of real-world epidemi...
-
Deep Intronic Variant in the ARSB Gene as the Genetic Cause for Maroteaux-Lamy Syndrome (MPS VI)Maroteaux-Lamy syndrome (MPS-VI) is a ra...
-
MPS VI (Maroteaux-Lamy Syndrome)https://www.onempsvoice.com/wp-content/u...
-
Clinical and Event-Based Outcomes of Patients With Mucopolysaccharidosis VI Receiving Enzyme Replacement Therapy in ...The objective of this study was to descr...
Powered by
